Gene Logic shares findings Oct 11, 2008
Gene Logic and deSciner to share genomics findings - Washington Business Journal ... Gene Logic and deSciner to share genomics findings ... Gaithersburg-based Gene Logic, a provider of genomic reference databases, and Leicester, England-based deSciner, a communication pool for scientific communities, will present applications of genomics in pursuit of better and cheaper therapeutics. (Washington Business Journal, DC)
Pharmacyclics, Inc. Announces Board and Management Transitions Sep 12, 2008
Mr. Duggan stated: "Pharmacyclics has an exceptional team of dedicated employees who have worked hard to build a sustainable portfolio of drugs to fight many diseases. I respect and admire this team and look forward to working together with them in the future." Dr. Miller commented: "We have built a significant portfolio of products under my tenure. I am gratified at the support I have received from the stockholders, Board of Directors and employees of the Company over the time that I have... (PR Newswire)
Ore Pharmaceuticals reports $4.7M loss Aug 4, 2008
Ore Pharmaceuticals, formerly known as Gene Logic, expects to eliminate approximately $7. 2 million in salary and benefit expenses per year. (Washington Business Journal, DC)
Ore Pharmaceuticals posts 4Q loss Feb 23, 2008
Formerly known as Gene Logic, the company changed its name Dec. 14 to Ore Pharmaceuticals. It morphed its business plan to focus on its drug repositioning and development business and to a lesser degree molecular diagnostics. (Washington Business Journal, DC)
Bridge Laboratories lands $18M in VC Jan 19, 2008
In December 2006, Bridge bought the preclinical division put up for sale by neighboring Gene Logic Inc., also of Gaithersburg. "We are excited about the possibilities this funding opens up for us and, ultimately, for our customers," said Tom Oakley, president and chief executive of Bridge Laboratories. (Washington Business Journal, DC)
Nasdaq warns Ore Pharmaceuticals of delisting Dec 21, 2007
The company formerly known as Gene Logic will lose its Nasdaq listing unless its share price can top $1 in the next six months. The Nasdaq Stock Market notified the Gaithersburg company, now known as , that its stock had closed below $1 per share for the past 30 days, according to a letter the market sent Ore on Dec. 14. (Washington Business Journal, DC)
Gene Logic sells genomics division Oct 16, 2007
Gene Logic disclosed in August that it had retained San Francisco-based life sciences investment bank to help sell its division that licenses genomic and toxicogenomics databases and software ... Gene Logic took a $1 ... Under the deal with Ocimum Biosolutions, which is based in Hyderabad, India, with a U.S. headquarters in Indianapolis, Gene Logic is holding on to its rights to use the genomics information databases to help develop its emerging drugs. (Baltimore Business Journal, MD)
Global Bioinformatics Market Outlook: Major Segments, Future Prospects, Key Applications Areas and Company Profiles Sep 7, 2007
Table 5-8: Gene Logic Inc. - Key Financials (in Million US$), 2004-2006. Table 5-9: Incyte Corporation - Key Financials (in Million US$), 2004-2006. (BusinessWire)
Charles Dimmler Aug 28, 2007
Gene Logic to redevelop drug - Baltimore Business Journal ... Gene Logic to redevelop drug ... Under the agreement, Gene Logic will reposition and develop several Solvay drugs that were discontinued or de-prioritized during clinical trials for reasons other than safety. (Baltimore Business Journal, MD)
Gene Logic cuts loss Jul 28, 2007
For the first half of the year, Gene Logic brought home $8 ... Last year, Gene Logic scaled back that division, laying off more than 80 employees and shuttering a California office ... Gene Logic said it has made strides in its drug repositioning division, which the company is shifting to its core business model. (Washington Business Journal, DC)
Gene Logic inks drug deal with Danish pharmaceutical firm Jun 30, 2007
These drug candidates were discontinued or de-prioritized in clinical trials for reasons other than safety, according to Gaithersburg-based Gene Logic. Gene Logic, which has developed genomics databases and services for customers worldwide, recently has been transforming itself into a biopharmaceutical company that is focused on drug repositioning ... Gene Logic (NASDAQ: GLGC) has the option to receive an exclusive license to any of the drug candidates it identifies for a potential new use that... (Washington Business Journal, DC)
Researchers Use 'Genomic Pathway' To Predict Parkinson's Jun 18, 2007
The study was supported by grants from the National Institutes of Health, the Michael J. Fox Foundation, the National Parkinson Foundation Inc., and Gene Logic Inc. ... D., of Gene Logic Inc.; Mariza de Andrade, Ph. (Science Daily)
Gene Logic strikes deal with Abbott Labs May 14, 2007
The latest agreement for Gaithersburg-based Gene Logic is with Abbott Park, Ill. -based Gene Logic will seek additional development paths for multiple Abbott drug candidates, all of which have completed Phase I clinical trials that test for safety ... Under the agreement, Gene Logic (NASDAQ: GLGC) is eligible to receive success-based milestone payments for each drug candidate that Abbott (NYSE: ABT) returns to clinical development. (Baltimore Business Journal, MD)
Semi-Annual Changes to the NASDAQ Biotechnology Index May 12, 2007
As a result of the re-ranking, Curis, Inc. (NasdaqGM: - ), Gene Logic Inc. (NasdaqGM: - ), Inhibitex, Inc. (NasdaqGM: - ) and Threshold Pharmaceuticals, Inc. (NasdaqGM: - ), will be removed from the Index. The NASDAQ Biotechnology Index is the basis for the iShares Nasdaq Biotechnology Index(sm) Fund (AMEX: - ), which seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of the NASDAQ Biotechnology Index. (Primezone Releases)
Gene Logic cuts former CEO from payroll May 3, 2007
Gene Logic also paid Gessler's personal tax-preparation bills of $5,000 and annual country club dues of $6,440 last year ... Gessler's dismissal comes as Gene Logic struggles with falling revenue while working to position itself as a drug-development company through relaunches of discontinued, but promising, drug candidates from larger pharmaceuticals ... When Gene Logic sold its preclinical division late last year, it opted to retain that division's general manager, V.W. Brinkerhoff III. The... (Washington Business Journal, DC)
People on the Move Apr 25, 2007
Gene Logic Inc. elected David L. Urdal of Dendreon Corp. and Mark J. Gabrielson of Pulmatrix Inc. to the Gaithersburg-based company's board of directors. Services. (Sunspot.net -- Business)
Gene Logic hires new CEO Mar 23, 2007
In the last year, Gene Logic has sold off its preclinical division and shaved down its genomics division ... Gene Logic reported a $54 ... Shares of Gene Logic (NASDAQ: GLGC) fell 8 cents per share, or 3. (Washington Business Journal, DC)
PJA Wins TriZetto Feb 9, 2007
PJA has been one of New England's more robust b-to-b- focused agencies, adding accounts such as Gene Logic and TAC in recent months. The shop is probably best known for its campaigns supporting Novell's Linux desktop solutions. (AdWeek)
